Breaking News

Market Launch of PoET System

Pushing blood screening forward

2021-03-31

Frankfurt/Main – GFE today unveiled its vision for the future of NAT testing in blood screening, the PoET system. A fully automated instrument, sophisticated software and a series of NAT tests make up this powerful solution for blood screening laboratories. Out of the gate, the PoET system features highly sensitive NAT tests for HCV, HBV, HIV, HAV, B19V and HEV, with WNV scheduled to follow this spring for seasonal testing. The PoET Instrument reaches a new level of integration and covers the entire workflow from sample pooling, to sample preparation and PCR testing on a single platform.

“One of our major objectives, while designing and developing the PoET product line, was to offer as much versatility in one small and powerful package as possible.” said Dr Holger Fey, Programme Director PoET System at GFE.

The PoET Instrument can process individual samples, mini-pools generated on separate equipment or generate mini-pools as part of a comprehensive workflow from primary sample tube to final result, without requiring any hands-on-time in the meantime. Naturally, positive identification and full traceability of samples and reagents are included.

“Even though virus NAT screening shares many similarities, where ever you look around the world, labs are often faced with difficult choices regarding NAT testing systems, because their implementation may require adjustments to a number of other processes already up and running in the lab.” Dr Fey noted. “Our goal is to make this an easy decision by offering a NAT system that is easy to integrate into existing workflows and consumes little lab space. All of this without any compromises in terms of performance, of course. Special care was taken not to exclude any size or type of laboratory by design.”

The NAT tests PoET HCV, PoET HBV, PoET HIV, PoET HAV, PoET B19V and PoET HEV are all approved and CE-marked for blood screening and confirmatory testing. The tests feature all of GFE’s signature technologies like the HIV-1 Triple Target test and a non-competitive Internal Control.

Empowering laboratories to stay on top of blood safety, GFE’ next generation NAT testing solution, the PoET system, is now available as the daily driver of your testing routine.

GFE looks back on more than 15 years of experience in blood screening, with millions and millions of blood donations tested with GFE’s NAT systems. Having emerged from it herself, GFE is dedicated to serving the blood screening community.

GFE is a wholly owned subsidiary of the three German Red Cross organizations DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and Blutspendedienst des Bayerischen Roten Kreuzes.

PoET Instrument, PoET HCV, PoET HBV, PoET HIV, PoET HAV, PoET B19V and PoET HEV are not available in all countries. Please contact GFE for details.

News & Events

GFE and LVL Technologies strengthen supply of COVID-19 antigen tests

Frankfurt am Main; Crailsheim, March  12, 2021. – GFE and…
gfe

PoET HIV CE-IVD marked

Frankfurt am Main, March 12, 2021. – GFE announced the CE-IVD…

The partner for your NAT blood screening needs.

  • We provide high-end solutions for the blood screening process.
  • We analyse and customise NAT screening workflows.
  • We enable our customers to streamline their processes.
  • We support our customers to achieve regulatory compliance.
© Copyright - GFE